Faculty within Patient-Driven Values in Healthcare Evaluation (PAVE) are engaged in a wide range of patient-driven research.

Research conducted within the center aims to elicit elements of value from diverse patients groups, prioritize patient-driven value elements, and test patient-driven value elements in an economic evaluation.


Active Research:

PATIENT-DRIVEN PRIORITIES FOR THE MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION

The motivation for this work is the strong belief that value in health care must be defined by patients. Moreover, value assessment must reflect heterogeneity across patients and their preferences. Despite the premise that patient centricity and heterogeneity are essential components of value frameworks, there has been insufficient attention to patient-driven value assessment. This may result in decisions based on one-size-fits-all conclusions. This is especially true with respect to individuals living with depression, which can be episodic in nature. Treatment response is variable, and many individuals do not respond to treatment, resulting in poor quality of life and excessive health care costs. There is an undeniable need for individualized approaches to find the alternative with the best effect in improving outcomes. With various options for treatment modalities, alone or in combination, it is of interest to individuals living with depression to have access to and be able to make informed decisions about the therapeutic approach that is best for their own situation. The Patient-driven Values in Healthcare Evaluations (PAVE) Center at the University of Maryland Baltimore School of Pharmacy developed with patient input a set of condition-agnostic value elements that are important to patients. This proposal builds off this work to elicit the importance of the value elements for individuals with treatment-resistant depression (TRD) and then estimate the preference utilities and the relative importance of each attribute. The goal of the proposed research is to identify the PAVE patient-informed value elements that can be incorporated into the value assessment of treatment options for individuals with TRD.

This project will be guided by three specific aims. The first aim is formative and the second and third aim are applied analyses.

  • Aim 1: To identify through a stakeholder-engaged process the PAVE patient-informed value elements that are important to individuals living with TRD.
  • Aim 2: To elicit patient priorities for treatment attributes to manage TRD.
  • Aim 3: To identify the patient-informed treatment attributes that can be incorporated in an economic model for TRD.

Funder: Innovation and Value Initiative
Collaborators: Susan dosReis, Julia Slejko, Joey Mattingly

Patient-Informed Values in Cost Effectiveness Analyses

Patient-Informed Values in Cost Effectiveness Analyses

In this three-minute video, Julia Slejko, PhD, assistant professor in the Department of Pharmaceutical Health Services Research and research core lead for Patient-Driven Values in Healthcare Evaluation (PAVE), explains the importance of incorporating the patient's perspective and values into cost effectiveness analyses.

VALUE ELEMENT ASSESSMENT AMONG INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

The PAVE team is conducting research to examine the elements of value in health care interventions and services that are most important to individuals living with COPD. Researchers will measure the utility and trade-offs in the benefits and risks of key value elements and then incorporate these into an economic evaluation. We will test different methodological approaches for patient-drive value assessment in health care interventions and services for individuals with COPD. This work will be conducted in collaboration with our patient community partners and is supported by PhRMA. To learn more about our research, contact Susan dosReis, PhD, professor and director of PAVE, at sdosreis@rx.umaryland.edu, and Julia Slejko, PhD, assistant professor in the Department of Pharmaceutical Health Services Research, at jslejko@rx.umaryland.edu.


Meeting Presentations:

Click or tap on the meetings listed below to view a complete list of posters, presentations, and workshops delivered at each meeting.

Society for Women's Health Research Virtual Policy Council Meeting

Women and Value Assessment: Striving to Capture the Patient Experience
PAVE researchers join experts from the Innovation and Value Initiative (IVI) and the Institute for Clinical and Economic Review (ICER) to discuss the current environment and the future of value assessment during the Society for Women's Health Research June 2020 Policy Advisory Council meeting.

ISPOR 2019 Conference Posters and Presentations

Podium Presentation:
Eliciting Value Elements for a Patient-Driven Value Assessment
Authors: Y. Hong, C. Zhang, J.F. Slejko, S. dosReis

Workshop:
An Analytic Approach to Incorporating Patient Preferences into Value Elements for Economic Evaluation
Authors: dosReis, S., Slejko, J.F., Lakdawalla, D.N., Wilke, R.J.

Posters:
Identifying COPD Patient-Informed Value Elements in Economic Evaluations: A Systematic Review
Authors: C. Gray, J.F. Slejko

Aligning COPD Outcomes with Patient-Informed Value Element Domains for Use in Economic Evaluations
Authors: J.F. Slejko, C. Gray, Y. Hong, J.D. Rueda, C. Zhang, S. dosReis


Prior Research:

Dr. Joey Mattingly presents his research to attendees at the PAVE kick-off meeting.

ENGAGING AN UNDERSERVED PATIENT COMMUNITY TO INFORM AND IMPROVE COMPARATIVE EFFECTIVENESS RESEARCH FOR HEPATITIS C TREATMENTS

A comprehensive review of the literature on published cost-effectiveness analyses for hepatitis C virus (HCV) treatments revealed that very little had been done to engage patients. Based on our clinical experience, we knew that many HCV patients report psychological and socioeconomic challenges but did not feel that these domains were being reflected in the economic models underpinning cost-effectiveness analyses. This capacity-building grant enabled the formation of a new research collaborative between patients, clinicians, researchers, and the American Liver Foundation. We seek to expand upon this preliminary work by investigating further the elements that are most important to patients in value-based decision making. Through this process, we will inform patient-driven cost-effectiveness analyses.

Patient-Centered Videos: Products generated from this work include:

Acknowledgement: This capacity-building grant was supported by a PCORI Pipeline to Proposal Award 2017-2018 (Principal Investigator: T. Joseph Mattingly II) Specific Project Details: PCORI Link

DELPHI PANEL TO ENGAGE PATIENT EXPERTS ON THE VALUE OF TREATMENT FOR FOOD ALLERGY

Food allergy is a major health problem that significantly impacts quality of life (QoL). There is growing attention to evaluate food allergy related QoL and treatments’ value by engaging patients, parents, and caregivers. We aimed to identify, prioritize, and drive agreement on important treatment outcomes and value of different treatment options to food allergy patients and parents of children allergic to milk, egg, and/or peanut.

In collaboration with the Asthma and Allergy Foundation of America (AAFA), we conducted a 3-round Delphi panel survey to identify and derive consensus on priority treatment outcomes for food allergy patients and parents from across the United States. Our findings indicate that food allergy patients and parents face several social, psychological, medical, healthcare, financial, food selection, and awareness challenges. Consensus on important treatment outcomes revealed shared priority for reducing the risk of potentially fatal allergic reactions and having reliable treatments. The most valued treatment options reflect hope for a permanent cure and fear of serious allergic reactions. Our findings will help guide comparative effectiveness research (CER) that focuses on evaluating food allergy treatment decisions.

Research Team: T. Joseph Mattingly II and Moaz Abdelwadoud

Acknowledgement: This project was funded by Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC (Principal Investigator: T. Joseph Mattingly II, PharmD, MBA, PhD).


Publications:

dosReis, S., Butler, B., Caicedo, J., Kennedy, A., Hong, Y.D., Zhang, C., Slejko, J.F. Stakeholder-engaged Derivation of Patient-Informed Value Elements. Patient. 2020. https://doi.org/10.1007/s40271-020-00433-8.

Harrington RL, Hanna ML, Oehrlein EM, et al. Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group. Value Health. 2020;23(6):677-688. doi:10.1016/j.jval.2020.01.019.

Mattingly, T.J., Slejko, J.F., Perfetto, E.M., dosReis, S. Putting Our Guard Down: Engaging Multiple Stakeholders to Define Value in Healthcare. Health Affairs Blog. January 2019.

Slejko, J.F., Mattingly, T.J., Mullins, C.D., Perfetto, E.M., dosReis, S. The Future of Patient-Driven Healthcare Evaluation: The Patient-Informed Reference Case. Value Health. 2019; 22(5):545–548.